Table 2

Characteristics of patients in the training set

Sample ID

Age (years)

Sex

Bacterial isolation

Antibiotherapy before blood collection

Underlying diseases

Survival


Other sepsis (n = 13)

I001*

52

Male

Streptococcus non-group A or B

Ceftriaxone

-

Non-survivor

I002†‡

52

Female

A. baumannii

Ceftazidime, bactrim

T2D, CRF, lung edema

Survivor

I004*

45

Male

Salmonella serotype B

Cloxacillin, ceftriaxone

T2D, arthritis

Survivor

I006* §

37

Male

C. albicans

Ceftriaxone, sulperazone, bactrim

HIV infection, tuberculosis

Survivor

I007*

73

Female

Corynebacterium spp.

-

NSAID-induced GI bleeding

Non-survivor

I008†¶

70

Female

E. coli

Bactrim, ceftazidime

T2D

Survivor

I009*

52

Female

S. aureus

Ceftazidime, cloxacillin

T2D, knee abscess

Survivor

I010†‡¥

72

Female

E. coli

Ceftriaxone

T2D, CRF

Survivor

I011*

38

Female

E. coli

-

HCV infection

Survivor

I012* §

69

Female

C. albicans

Ceftazidime

RF

Survivor

I013*

74

Female

Corynebacterium spp.

Ceftazidime, clarithromycin

Chronic heart failure, COPD

Survivor

I014*

54

Female

Salmonella spp.

Ceftriaxone, ceftazidime, levofloxacin

T2D, endometrial cancer, ITP

Survivor

I015* §

41

Male

C. albicans

Ceftazidime

HIV infection

Survivor

Septicemic melioidosis (n = 11)

M001*

68

Male

B. pseudomallei

Ceftazidime, bactrim

Chronic heart failure, COPD

Non-survivor

M002*

43

Female

B. pseudomallei

Ceftriaxone, ceftazidime

T2D

Survivor

M003*

55

Male

B. pseudomallei

Ceftazidime

-

Non-survivor

M006*

46

Male

B. pseudomallei

Ceftriaxone

T2D, chirrosis

Non-survivor

M007*

50

Male

B. pseudomallei

Ceftazidime, tazocin

Lung cancer

Survivor

M008*

70

Female

B. pseudomallei

Ceftazidime, bactrim

T2D

Non-survivor

M009*

48

Female

B. pseudomallei

Sulperazone

T2D

Survivor

M010*

48

Male

B. pseudomallei

Ceftriaxone, ceftazidime, doxycycline

T2D

Survivor

M012*

56

Male

B. pseudomallei

Sulperazone, bactrim, cetazidime

T1D, ARF

Survivor

M014*

65

Female

B. pseudomallei

Cloxacilin, ceftazidime

T2D, chirrosis

Non-survivor

M015*

41

Male

B. pseudomallei

Bactrim, ceftazidime

-

Survivor


*Community-acquired septicemia; hospital-acquired septicemia;mechanical ventilation;§taken immunosuppressive;urinary catheterized drugs; ¥blood transfused. ARF, acute renal failure; COPD, chronic obstructive pulmonary disease; CRF, chronic renal failure; GI, gastrointestinal tract; NSAID, non-steroidal anti-inflammatory drug; RF, renal failure; T2D, type 2 diabetes; TP, idiopathic thrombocytopenic purpura.

Pankla et al. Genome Biology 2009 10:R127   doi:10.1186/gb-2009-10-11-r127

Open Data